Literature DB >> 24110741

A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation.

Chinyere I Nwabugwu, Kavya Rakhra, Dean W Felsher, David S Paik.   

Abstract

Understanding the complex dynamics between the tumor cells and the host immune system will be key to improved therapeutic strategies against cancer. We propose an ODE-based mathematical model of both the tumor and immune system and how they respond to inactivation of the driving oncogene. Our model supports experimental results showing that cellular senescence of tumor cells is dependent on CD4+ T helper cells, leading to relapse of tumors in immunocompromised hosts.

Entities:  

Mesh:

Year:  2013        PMID: 24110741      PMCID: PMC4487533          DOI: 10.1109/EMBC.2013.6610554

Source DB:  PubMed          Journal:  Conf Proc IEEE Eng Med Biol Soc        ISSN: 1557-170X


  9 in total

1.  Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

Authors:  I B Weinstein; M Begemann; P Zhou; E K Han; A Sgambato; Y Doki; N Arber; M Ciaparrone; H Yamamoto
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

2.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

Review 3.  Augmenting T helper cell immunity in cancer.

Authors:  K L Knutson; M L Disis
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2005-12

Review 4.  Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies.

Authors:  Lisa Hoenicke; Lars Zender
Journal:  Carcinogenesis       Date:  2012-04-02       Impact factor: 4.944

5.  A mathematical model of tumor-immune interactions.

Authors:  Mark Robertson-Tessi; Ardith El-Kareh; Alain Goriely
Journal:  J Theor Biol       Date:  2011-10-28       Impact factor: 2.691

6.  Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.

Authors:  Peter S Choi; Jan van Riggelen; Andrew J Gentles; Pavan Bachireddy; Kavya Rakhra; Stacey J Adam; Sylvia K Plevritis; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

7.  Primary antitumor immune response mediated by CD4+ T cells.

Authors:  Alexandre Corthay; Dag K Skovseth; Katrin U Lundin; Egil Røsjø; Hilde Omholt; Peter O Hofgaard; Guttorm Haraldsen; Bjarne Bogen
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

8.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

Review 9.  Myc oncogenes: the enigmatic family.

Authors:  K M Ryan; G D Birnie
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

  9 in total
  2 in total

Review 1.  Mathematical modeling of tumor-immune cell interactions.

Authors:  Grace E Mahlbacher; Kara C Reihmer; Hermann B Frieboes
Journal:  J Theor Biol       Date:  2019-03-02       Impact factor: 2.691

Review 2.  Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.

Authors:  Vijayalakshmi Chelliah; Georgia Lazarou; Sumit Bhatnagar; John P Gibbs; Marjoleen Nijsen; Avijit Ray; Brian Stoll; R Adam Thompson; Abhishek Gulati; Serguei Soukharev; Akihiro Yamada; Jared Weddell; Hiroyuki Sayama; Masayo Oishi; Sabine Wittemer-Rump; Chirag Patel; Christoph Niederalt; Rolf Burghaus; Christian Scheerans; Jörg Lippert; Senthil Kabilan; Irina Kareva; Natalya Belousova; Alex Rolfe; Anup Zutshi; Marylore Chenel; Filippo Venezia; Sylvain Fouliard; Heike Oberwittler; Alix Scholer-Dahirel; Helene Lelievre; Dean Bottino; Sabrina C Collins; Hoa Q Nguyen; Haiqing Wang; Tomoki Yoneyama; Andy Z X Zhu; Piet H van der Graaf; Andrzej M Kierzek
Journal:  Clin Pharmacol Ther       Date:  2020-08-14       Impact factor: 6.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.